Phillip B. Donenberg - 29 May 2024 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
29 May 2024
Net transactions value
$0
Form type
4
Filing time
31 May 2024, 16:18:21 UTC
Previous filing
16 Aug 2023
Next filing
24 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Award $0 +49,220 +43% $0.000000 163,331 29 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Stock Option (right to buy) Award $0 +98,440 $0.000000 98,440 29 May 2024 Common Stock 98,440 $3.17 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
F2 The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.